Genentech updates Herceptin warning

DNA issued a "Dear Healthcare Professional" letter for Herceptin trastuzumab to include data on cardiotoxicity seen in recent trials. In the Phase III NSABP B-31 study in 2,043 patients and the NCCTG ...